Published in J Clin Invest on April 01, 1995
Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest (2004) 1.96
Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob Agents Chemother (1998) 1.06
Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect Immun (2001) 1.05
Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med (2011) 0.98
Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother (2000) 0.92
A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats. Infect Immun (1997) 0.90
Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation. F1000Res (2015) 0.75
Halobacterial nano vesicles displaying murine bactericidal permeability-increasing protein rescue mice from lethal endotoxic shock. Sci Rep (2016) 0.75
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
Endotoxins and disease mechanisms. Annu Rev Med (1987) 6.07
Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med (1990) 5.15
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
The pathogenesis of sepsis. Ann Intern Med (1991) 4.34
Increased plasma levels of interleukin-6 in sepsis. Blood (1989) 3.92
Retracted Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol (1990) 3.76
Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis (1989) 3.66
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A (1992) 3.61
Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med (1980) 3.03
Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure. J Clin Invest (1980) 2.99
Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol (1987) 2.59
Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr (1994) 2.51
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A (1991) 2.24
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest (1993) 2.00
Tumor necrosis factor-independent IL-6 production during murine listeriosis. J Immunol (1991) 1.97
Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol (1990) 1.96
The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol (1992) 1.92
Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis (1984) 1.89
Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest (1992) 1.82
Lipopolysaccharide nomenclature--past, present, and future. J Bacteriol (1986) 1.80
Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med (1991) 1.80
The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol (1984) 1.67
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis (1990) 1.62
Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis (1990) 1.46
Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. J Immunol (1989) 1.44
Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med (1989) 1.39
Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit Care Med (1994) 1.23
Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr (1992) 1.15
Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. J Infect Dis (1990) 1.13
Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J Exp Med (1993) 1.07
Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. J Surg Res (1993) 0.96
Gram-negative bacillary infections. Pathogenic and pathophysiologic correlates. Am J Med (1985) 0.92
Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice. FEMS Microbiol Immunol (1992) 0.90
Detection of endotoxin in the plasma of patients with gram-negative bacterial sepsis by the Limulus amoebocyte lysate assay. J Clin Microbiol (1985) 0.90
The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol (1994) 0.86
New perspectives in circulatory shock: pathophysiologic mediators of the mammalian response to endotoxemia and sepsis. J Am Vet Med Assoc (1992) 0.86
Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock (1985) 0.84
Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coagul Fibrinolysis (1993) 0.79
Improved techniques for cardiovascular monitoring in rats as applied during endotoxemia. Am J Physiol (1988) 0.77
Accessing genetic information with high-density DNA arrays. Science (1996) 13.89
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Using oligonucleotide probe arrays to access genetic diversity. Biotechniques (1995) 12.18
Elution of DNA from agarose gels after electrophoresis. Methods Enzymol (1979) 8.36
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 5.23
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet (1996) 4.77
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
The Involvement of the Aortic Valve in Syphilitic Aortitis. Am J Pathol (1927) 3.67
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55
Chaotic Dirac billiard in graphene quantum dots. Science (2008) 3.53
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell (1980) 2.76
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1989) 2.59
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem (1999) 2.47
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 2.33
Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest (1991) 2.32
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
"Type III" cells of rat taste buds: immunohistochemical and ultrastructural studies of neuron-specific enolase, protein gene product 9.5, and serotonin. J Comp Neurol (2001) 2.28
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol (1991) 2.10
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation (1995) 2.07
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
Tissue-specific activation of a cloned alpha-fetoprotein gene during differentiation of a transfected embryonal carcinoma cell line. Nature (1984) 2.02
Direct visualization of phosphorylase-phosphorylase kinase complexes by scanning tunneling and atomic force microscopy. Biophys J (1990) 1.97
Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol (1990) 1.96
Absence of WAF1 mutations in a variety of human malignancies. Blood (1994) 1.95
The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol (1992) 1.92
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation (1995) 1.92
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem (1991) 1.89
Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. Am J Transplant (2008) 1.86
Effect of a high-kappa environment on charge carrier mobility in graphene. Phys Rev Lett (2009) 1.85
Proviral sequences that restrict retroviral expression in mouse embryonal carcinoma cells. Mol Cell Biol (1987) 1.84
Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci (1997) 1.84
Surgery of small hepatocellular carcinoma. Analysis of 144 cases. Cancer (1989) 1.82
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
Transient expression of a mouse alpha-fetoprotein minigene: deletion analyses of promoter function. Mol Cell Biol (1983) 1.74
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Intragenic amplification and divergence in the mouse alpha-fetoprotein gene. Nature (1981) 1.69
PROC c.574_576del polymorphism: a common genetic risk factor for venous thrombosis in the Chinese population. J Thromb Haemost (2012) 1.69
Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol (1988) 1.69
Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J Immunol (1990) 1.69
Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J (1992) 1.68
alpha-Fetoprotein and albumin genes are in tandem in the mouse genome. Proc Natl Acad Sci U S A (1981) 1.67
Protease nexin. Properties and a modified purification procedure. J Biol Chem (1985) 1.66
Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost (2001) 1.64
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol (1999) 1.63
Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol (1996) 1.63
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation (1999) 1.58
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins (1976) 1.56
Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J Biol Chem (1989) 1.56
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A (1990) 1.55
Released protease-nexin regulates cellular binding, internalization, and degradation of serine proteases. Proc Natl Acad Sci U S A (1981) 1.53
Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem (2001) 1.53
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53
Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation (1995) 1.51
Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci (1998) 1.50
Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol (1999) 1.50
Evidence for a stem cell-specific repressor of Moloney murine leukemia virus expression in embryonal carcinoma cells. Mol Cell Biol (1990) 1.50
Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci (2000) 1.50
Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology (1999) 1.50
Targeted deletion of the cytosolic Cu/Zn-superoxide dismutase gene (Sod1) increases susceptibility to noise-induced hearing loss. Audiol Neurootol (1999) 1.50
Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol (1988) 1.49
Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci U S A (1986) 1.47